Revium Rx. (RVRC): Cash & Equivalents
$1.68M
As of 2025-12-31
$842.0K
As of 2026-06-30
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.68M | -48.7% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $3.27M | n/a | 2026-03-31, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Revium Rx. (RVRC) | 2025-12-31 | $1.68M | -48.7% |
| GT Biopharma, Inc. (GTBP) | 2025-12-31 | $6.81M | +72.4% |
| Palatin Technologies Inc (PTN) | 2026-06-30 | $7.49M | +192.2% |
| CNS Pharmaceuticals, Inc. (CNSP) | 2025-12-31 | $7.20M | +11.4% |
| GRI Bio, Inc. (GRI) | 2025-12-31 | $8.23M | +63.7% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $405.0K | -66.2% |
| Dermata Therapeutics, Inc. (DRMA) | 2025-12-31 | $7.52M | +137.9% |
| Processa Pharmaceuticals, Inc. (PCSA) | 2025-12-31 | $5.54M | +364.8% |
| Earth Science Tech, Inc. (ETST) | 2026-03-31 | $796.8K | -45.9% |
Compare RVRC, GTBP, PTN, CNSP side by side · Screen every company in Pharmaceutical Preparations ↗